Top

Published in:

01-07-2020 | Endometrial Cancer | Review

TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma

Authors: Antonio Travaglino, Antonio Raffone, Massimo Mascolo, Maurizio Guida, Luigi Insabato, Gian Franco Zannoni, Fulvio Zullo

Published in: Pathology & Oncology Research | Issue 3/2020

Abstract

We aimed to classify undifferentiated/dedifferentiated carcinoma (UDC/DDC) according to the four TCGA molecular subgroups of endometrial cancer: microsatellite-instable/hypermutated (MSI), POLE-mutant/ultramutated (POLE), copy-number-low/p53-wild-type (p53wt), and copy-number-high/p53-abnormal (p53abn), through a systematic review and meta-analysis. Electronic databases were searched from January 2013 to July 2019 for studies assessing the TCGA classification in endometrial UDC/DDC series. Pooled prevalence of each TCGA subgroup on the total UDC/DDCs was calculated. Three studies with 73 patients were included. Pooled prevalence of the TCGA subgroups were: 12.4% for the POLE subgroup, 44% for the MSI subgroup, 18.6% for the p53abn subgroup, 25% for the p53wt group. All TCGA groups are represented in UDC/DDC, with a predominance of the MSI group, indicating a biological heterogeneity. Hypermutated/ultramutated cancers constitute the majority of UDC/DDC, suggesting a crucial difference with other high-risk histologies of endometrial carcinoma.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29PubMed

Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial Cancer. Am J Clin Pathol 151(5):529–538CrossRefPubMed

Raffone A, Travaglino A, Mascolo M et al (2019) TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2019.08.019

Raffone A, Travaglino A, Santoro A et al (2019) Accuracy of one-step nucleic acid amplification in detecting lymph node metastases in endometrial Cancer. Pathol Oncol Res. https://doi.org/10.1007/s12253-019-00727-9

Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13587

Cancer Genome Atlas Research Network et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73CrossRef

Stelloo E, Nout RA, Osse EM et al (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 22(16):4215–4224CrossRefPubMed

Bosse T, Nout RA, McAlpine JN et al (2018) Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 42(5):561–568PubMedPubMedCentral

Cosgrove CM, Tritchler DL, Cohn DE et al (2018 Jan) An NRG oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. GynecolOncol. 148(1):174–180

10.

Talhouk A, McConechy MK, Leung S et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113(2):299–310CrossRefPubMedPubMedCentral

11.

Talhouk A, McConechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 123(5):802–813CrossRefPubMed

12.

Kommoss S, McConechy MK, Kommoss F et al (2018 May 1) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. AnnOncol. 29(5):1180–1188

13.

Hoang LN, Kinloch MA, Leo JM et al (2017 Feb) Interobserver agreement in endometrial carcinoma Histotype diagnosis varies depending on the Cancer genome atlas (TCGA)-based molecular subgroup. Am J Surg Pathol 41(2):245–252CrossRefPubMed

14.

Raffone A, Travaglino A, Saccone G et al (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13553

15.

Lionetti R, De Luca M, Travaglino A et al (2019 Jul) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23CrossRefPubMed

16.

Travaglino A, Raffone A, Saccone G et al (2019) Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy. APMIS. https://doi.org/10.1111/apm.12988

17.

Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13586

18.

Travaglino A, Raffone A, Saccone A et al (2019) Immunophenotype of atypical Polypoid Adenomyoma of the uterus: diagnostic value and insight on pathogenesis. Appl Immunohistochem Mol Morphol. https://doi.org/10.1097/PAI.0000000000000780

19.

Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 4:1CrossRefPubMedPubMedCentral

20.

Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMed

21.

Travaglino A, Raffone A, Saccone G et al (2019) Congruence between 1994 WHO classification of endometrial hyperplasia and endometrial intraepithelial neoplasia system. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqz132

22.

Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524CrossRefPubMed

23.

Travaglino A, Raffone A, Mascolo M et al (2019) Clear cell endometrial carcinoma and the TCGA classification. Histopathology. https://doi.org/10.1111/his.13976

24.

Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169CrossRefPubMed

25.

Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242CrossRefPubMed

26.

Travaglino A, Raffone A, Saccone G et al (2019) Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-019-05299-2

27.

Raffone A, Travaglino A, Saccone G et al (201) Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res. https://doi.org/10.1007/s12253-019-00684-3

28.

Raffone A, Travaglino A, Saccone G et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. https://doi.org/10.1111/apm.12977

29.

Raffone A, Travaglino A, Saccone G et al (2019) Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol 5:1–6. https://doi.org/10.1080/09513590.2019.1624716 CrossRef

30.

Meng B, Hoang LN, McIntyre JB et al (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19CrossRefPubMed

31.

Stewart CJ, Crook ML (2015) SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma. Pathology. 47(5):439–445CrossRefPubMed

32.

Coatham M, Li X, Karnezis AN et al (2016) Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol 29(12):1586–1593CrossRefPubMed

33.

Ramalingam P, Croce S, McCluggage WG (2017) Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology. 70(3):359–366CrossRefPubMed

34.

Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E et al (2016) Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Mod Pathol 29(11):1390–1398CrossRefPubMedPubMedCentral

35.

Espinosa I, Lee CH, D’Angelo E, Palacios J, Prat J (2017) Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Am J Surg Pathol 41(8):1121–1128CrossRefPubMed

36.

Köbel M, Hoang LN, Tessier-Cloutier B et al (2018) Undifferentiated endometrial carcinomas show frequent loss of core switch/sucrose nonfermentable complex proteins. Am J Surg Pathol 42(1):76–83PubMedPubMedCentral

37.

Murali R, Davidson B, Fadare O et al (2019) High-grade endometrial carcinomas: morphologic and Immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol 38 Suppl 1:S40–S63CrossRefPubMed

38.

Silverberg SG, Nogales F, Tavassoli FA, Devilee P (eds) (2003) Tumours of the uterine corpus. Pathology and genetics: Tumours of the breast and female genital organs. IARC Press. World Health Organization Classification of Tumours, Lyon, pp 217–257

39.

Zaino R, Carinelli SG, Eng C, Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014) Tumours of the uterine corpus. WHO classification of tumours of female reproductive organs. IARC Press. World Health Organization Classification of Tumours, Lyon, pp 121–154

40.

Karnezis AN, Hoang LN, Coatham M et al (2016) Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol 29:302–314CrossRefPubMedPubMedCentral

41.

Abu-Rustum NR, Yashar CM, Bean S, et al (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) – Uterine Neoplasms. Version 3.Feb 11 2019

42.

Stelloo E, Bosse T, Nout RA et al (2015) Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 28(6):836–844CrossRefPubMed

43.

Cherniack AD, Shen H, Walter V et al (2017) Integrated molecular characterization of uterine Carcinosarcoma. Cancer Cell 31(3):411–423CrossRefPubMedPubMedCentral

44.

Hacking S, Jin C, Komforti M, Liang S, Nasim M (2019) MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications. Pathol Res Pract 22:152552. https://doi.org/10.1016/j.prp.2019.152552 CrossRef

45.

Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16(11):2598–2608CrossRefPubMedPubMedCentral

Title: TCGA Molecular Subgroups in Endometrial Undifferentiated/Dedifferentiated Carcinoma
Authors: Antonio Travaglino
Antonio Raffone
Massimo Mascolo
Maurizio Guida
Luigi Insabato
Gian Franco Zannoni
Fulvio Zullo
Publication date: 01-07-2020
Publisher: Springer Netherlands
Keywords: Endometrial Cancer
Endometrial Cancer
Published in: Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00784-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma

Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations

Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival

Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse

Correction to: Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma

Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer